Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

698 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ketogenic diet for focal epilepsy with SPTAN1 encephalopathy.
Kishimoto K, Nabatame S, Kagitani-Shimono K, Kato M, Tohyama J, Nakashima M, Matsumoto N, Ozono K. Kishimoto K, et al. Epileptic Disord. 2022 Aug 1;24(4):726-728. doi: 10.1684/epd.2022.1441. Epileptic Disord. 2022. PMID: 35925050 English. No abstract available.
Clinical manifestations and epilepsy treatment in Japanese patients with pathogenic CDKL5 variants.
Kobayashi Y, Tohyama J, Takahashi Y, Goto T, Haginoya K, Inoue T, Kubota M, Fujita H, Honda R, Ito M, Kishimoto K, Nakamura K, Sakai Y, Takanashi JI, Tanaka M, Tanda K, Tominaga K, Yoshioka S, Kato M, Nakashima M, Saitsu H, Matsumoto N. Kobayashi Y, et al. Among authors: kishimoto k. Brain Dev. 2021 Apr;43(4):505-514. doi: 10.1016/j.braindev.2020.12.006. Epub 2021 Jan 9. Brain Dev. 2021. PMID: 33436160 Free article.
Ketogenic diet for focal epilepsy with.
Kishimoto K, Nabatame S, Kagitani-Shimono K, Kato M, Tohyama J, Nakashima M, Matsumoto N, Ozono K. Kishimoto K, et al. Epileptic Disord. 2022 Jun 1;24(4):1-3. doi: 10.1684/epd.2022.1441. Epileptic Disord. 2022. PMID: 35653110 English. No abstract available.
A case of perinatal hypophosphatasia with a novel mutation in the ALPL gene: clinical course and review of the literature.
Oyachi M, Harada D, Sakamoto N, Ueyama K, Kondo K, Kishimoto K, Izui M, Nagamatsu Y, Kashiwagi H, Yamamuro M, Tamura M, Kikuchi S, Akiyama T, Michigami T, Seino Y, Namba N. Oyachi M, et al. Among authors: kishimoto k. Clin Pediatr Endocrinol. 2018;27(3):179-186. doi: 10.1297/cpe.27.179. Epub 2018 Jul 31. Clin Pediatr Endocrinol. 2018. PMID: 30083035 Free PMC article.
Monthly intravenous alendronate treatment can maintain bone strength in osteogenesis imperfecta patients following cyclical pamidronate treatment.
Harada D, Kashiwagi H, Ueyama K, Oriyama K, Hanioka Y, Sakamoto N, Kondo K, Kishimoto K, Izui M, Nagamatsu Y, Yamada H, Tanaka H, Namba N, Seino Y. Harada D, et al. Among authors: kishimoto k. J Pediatr Endocrinol Metab. 2020 Nov 26;33(11):1391-1397. doi: 10.1515/jpem-2020-0071. J Pediatr Endocrinol Metab. 2020. PMID: 33031051 Clinical Trial.
698 results